McMaster University

McMaster University

Faculty of
Health Sciences

Hamilton the centre of global COMPASS study

Published: November 13, 2012
Salim Yusuf
Dr. Salim Yusuf, professor of medicine, Michael G. DeGroote School of Medicine; executive director of the PHRI; and principal investigator of the COMPASS study.

The largest clinical study ever done to investigate the potential of a drug to prevent cardiac events in patients is being launched by the Population Health Research Institute (PHRI).

The institute, shared by McMaster University and Hamilton Health Sciences, is conducting the study in collaboration with Bayer Inc. The study, called COMPASS, will assess whether the drug rivaroxaban will prevent cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).

The Phase III trial will enroll about 20,000 patients from more than 25 countries. In Canada, the study will enroll about 2,250 patients and will represent a significant investment in Canadian-led research over the next several years.

"Although there are therapies that offer significant protection for patients with coronary or peripheral artery disease, a significant risk of heart attacks, stroke or even death remains in these high-risk patients," said Dr. Salim Yusuf, executive director of the PHRI and principal investigator of the COMPASS study.

"This is an important study, designed to investigate additional, potentially complementary, cardioprotective benefits for these patients."

Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0